Mutual Regulation of MDM4 and TOP2A in Cancer Cell Proliferation

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2019 Jan 24

PMID 30672125

Citations 38

Authors

Tao Liu

Hailong Zhang

Sha Yi

Lubing Gu

Muxiang Zhou

Affiliations

Soon will be listed here.

Abstract

MDM4 and topoisomerase IIα (TOP2A) are overexpressed in various human cancers. MDM4 acts as an oncoprotein which promotes cancer progression by inhibiting tumor suppressor p53. As a DNA replication- and cell division-regulating enzyme, TOP2A is the main target of many anticancer therapy regimens; however, the exact role of TOP2A in cancer remains elusive. Herein, we report that MDM4 and TOP2A bind to each other and are mutually upregulated at the post-translational level, leading to TOP2A protein stabilization, inhibition of p53, and increased tumor-cell proliferation. We demonstrate that the C-terminal region (CTR) of TOP2A binds to a unique sequence (residues: 188-238) of MDM4, which contains an auto-inhibitory segment regulating the MDM4-p53 interaction. TOP2A binding in turn activates MDM4 for p53 binding, resulting in enhanced inhibition of p53 and cancer cell proliferation. Conversely, binding of the MDM4 sequence to the CTR of TOP2A stabilizes TOP2A protein, leading to increased TOP2A protein expression. These results reveal novel functions of MDM4 and TOP2A as well as their interactions in oncogenesis, suggesting that inhibition of the MDM4-TOP2A interaction may represent a novel strategy in specifically and simultaneously targeting TOP2A and MDM4 for cancer treatment.

Citing Articles

TRIM36 serves as a prognostic indicator linked to immune infiltration in KIRC.

Zhang J, Zou B, Geng Y, Yin H, Qin B, Gao W Heliyon. 2025; 11(4):e42540.

PMID: 40028597 PMC: 11870256. DOI: 10.1016/j.heliyon.2025.e42540.

Multi-omics analysis reveals the panoramic picture of TOP2A in pan-cancer.

Zhang J, Yang T, Wang K, Pan J, Qiu J, Zheng S Sci Rep. 2025; 15(1):6046.

PMID: 39972040 PMC: 11840046. DOI: 10.1038/s41598-025-85929-9.

Phillyrin regulates the JAK2/STAT3 signaling pathway by inhibiting TOP2A expression to accelerate ferroptosis in hepatocellular carcinoma.

Zhu Y, Huang F, Liu X, Hou Y, Huang Y Oncol Rep. 2025; 53(4).

PMID: 39950325 PMC: 11843411. DOI: 10.3892/or.2025.8876.

Multiple Myeloma: Genetic and Epigenetic Biomarkers with Clinical Potential.

Veryaskina Y, Titov S, Skvortsova N, Kovynev I, Antonenko O, Demakov S Int J Mol Sci. 2025; 25(24.

PMID: 39769169 PMC: 11679576. DOI: 10.3390/ijms252413404.

Integrated bioinformatics reveals genetic links between visceral obesity and uterine tumors.

Samantaray S, Joshi N, Vasa S, Shibu S, Kaloni A, Parekh B Mol Genet Genomics. 2024; 299(1):93.

PMID: 39368016 DOI: 10.1007/s00438-024-02184-9.

References

Jain M, Zhang L, He M, Zhang Y, Shen M, Kebebew E . TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer. 2013; 20(3):361-70. PMC: 4990817. DOI: 10.1530/ERC-12-0403. View

Riemenschneider M, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus J . Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res. 2000; 59(24):6091-6. View

Chen L, Borcherds W, Wu S, Becker A, Schonbrunn E, Daughdrill G . Autoinhibition of MDMX by intramolecular p53 mimicry. Proc Natl Acad Sci U S A. 2015; 112(15):4624-9. PMC: 4403185. DOI: 10.1073/pnas.1420833112. View

Li L, Tan Y, Chen X, Xu Z, Yang S, Ren F . MDM4 overexpressed in acute myeloid leukemia patients with complex karyotype and wild-type TP53. PLoS One. 2014; 9(11):e113088. PMC: 4236138. DOI: 10.1371/journal.pone.0113088. View

Zhang Q, Zeng S, Lu H . Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem. 2014; 85:281-319. PMC: 4472007. DOI: 10.1007/978-94-017-9211-0_16. View

Woessner R, Mattern M, Mirabelli C, Johnson R, Drake F . Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 1991; 2(4):209-14. View

Lou Z, Minter-Dykhouse K, Chen J . BRCA1 participates in DNA decatenation. Nat Struct Mol Biol. 2005; 12(7):589-93. DOI: 10.1038/nsmb953. View

Wade M, Li Y, Wahl G . MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013; 13(2):83-96. PMC: 4161369. DOI: 10.1038/nrc3430. View

Wang Q, Zambetti G, Suttle D . Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor. Mol Cell Biol. 1997; 17(1):389-97. PMC: 231763. DOI: 10.1128/MCB.17.1.389. View

10.

Gu L, Zhang H, He J, Li J, Huang M, Zhou M . MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells. Oncogene. 2011; 31(11):1342-53. PMC: 3213308. DOI: 10.1038/onc.2011.343. View

11.

Lyu Y, Kerrigan J, Lin C, Azarova A, Tsai Y, Ban Y . Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007; 67(18):8839-46. DOI: 10.1158/0008-5472.CAN-07-1649. View

12.

Sandri M, Isaacs R, Ongkeko W, Harris A, Hickson I, Broggini M . p53 regulates the minimal promoter of the human topoisomerase IIalpha gene. Nucleic Acids Res. 1996; 24(22):4464-70. PMC: 146283. DOI: 10.1093/nar/24.22.4464. View

13.

Shvarts A, Bazuine M, Dekker P, Ramos Y, Steegenga W, Merckx G . Isolation and identification of the human homolog of a new p53-binding protein, Mdmx. Genomics. 1997; 43(1):34-42. DOI: 10.1006/geno.1997.4775. View

14.

He J, Gu L, Zhang H, Zhou M . Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma. Cell Cycle. 2011; 10(17):2994-3002. PMC: 3218600. DOI: 10.4161/cc.10.17.17118. View

15.

Higashitsuji H, Higashitsuji H, Masuda T, Liu Y, Itoh K, Fujita J . Enhanced deacetylation of p53 by the anti-apoptotic protein HSCO in association with histone deacetylase 1. J Biol Chem. 2007; 282(18):13716-25. DOI: 10.1074/jbc.M609751200. View

16.

Watt P, Hickson I . Structure and function of type II DNA topoisomerases. Biochem J. 1994; 303 ( Pt 3):681-95. PMC: 1137600. DOI: 10.1042/bj3030681. View

17.

Carpenter A, Porter A . Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line. Mol Biol Cell. 2004; 15(12):5700-11. PMC: 532048. DOI: 10.1091/mbc.e04-08-0732. View

18.

Meng H, Chen R, Li W, Xu L, Xu L . Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry. Pathol Int. 2012; 62(6):391-9. DOI: 10.1111/j.1440-1827.2012.02808.x. View

19.

Zhao H, Yu H, Liu Y, Wang Y, Cai W . DNA topoisomerase II-alpha as a proliferation marker in human gliomas: correlation with PCNA expression and patient survival. Clin Neuropathol. 2008; 27(2):83-90. DOI: 10.5414/npp27083. View

20.

Wu S, Chen L, Becker A, Schonbrunn E, Chen J . Casein kinase 1α regulates an MDMX intramolecular interaction to stimulate p53 binding. Mol Cell Biol. 2012; 32(23):4821-32. PMC: 3497597. DOI: 10.1128/MCB.00851-12. View